Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s seizure syndrome and seizure type. The epilepsy therapy market already comprises more than 25 antiepileptic drugs (AEDs), most of them generic, that can be effective for many patients. In this challenging market environment, developers increasingly target underserved, niche segments or subpopulations (e.g., orphan pediatric syndromes, rescue therapy) as a path to differentiation. Understanding the trajectory of the established epilepsy market and the evolving competitive landscape in niche segments is critical for marketers of both current and emerging brands to retain market share or carve out a clinical role.

Questions Answered:

  • What is the current state of treatment in epilepsy in the G7, and what needs are left unfulfilled by approved AEDs?
  • What are the market opportunities and sales potential for agents targeting treatment-refractory focal epilepsy (e.g., Xcopri) and for agents targeting orphan epilepsy subpopulations (e.g., Epidiolex, Fintepla)?
  • What clinical role will recently approved and emerging acute rescue therapies (e.g., Nayzilam, Valtoco, Libervant) play in the epilepsy market?
  • How will neurologists differentiate between current and emerging third-generation AEDs, and which of these agents will experience the most clinical and commercial success in the face of strong generics competition from first- and second-generation AEDs?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 27 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other DRG research.

Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.

Emerging therapies: Phase III/PR: 5 drugs; coverage of select Phase II products.

Market forecast features: Patient-based market forecast extending through 2029, segmented by brands/generics.

Key companies: Aquestive Therapeutics, Bial, Eisai, Eton Pharmaceuticals, GW Pharmaceuticals, Lundbeck, Marinus Pharmaceuticals, Neurelis, Sanofi, SK Biopharmaceuticals, UCB, Sunovion, Zogenix.

Key drugs: Levetiracetam, lamotrigine, carbamazepine, valproates, Vimpat (lacosamide), Aptiom/Zebinix (eslicarbazepine acetate), Fycompa (perampanel), Briviact (brivaracetam), Epidiolex / Epidyolex (cannabidiol), Fintepla (fenfluramine), Xcopri (cenobamate), Nayzilam (intranasal midazolam), Libervant (buccal diazepam), Valtoco (intranasal diazepam).

Table of contents

  • Epilepsy - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Niyati Khetarpal, Ph.D.; Abey John, M.P.H.; Bethany Christmann, Ph.D.

Niyati Khetarpal, M.Sc., M.B.A., Ph.D., is an analyst on the CNS/Ophthalmology Disorders team at DRG, part of Clarivate. She has authored content on multiple indications, including multiple sclerosis, opioid addiction, and epilepsy. Dr. Khetarpal obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology in New Delhi, where she conducted research on Dengue virus vaccines. In 2014, she received a Fulbright-Nehru doctoral scholarship for her research on Dengue and West Nile virus envelope proteins.

Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.

 

Bethany Christmann, Ph.D., is a principal analyst on the CNS/Ophthalmology team at DRG, part of Clarivate. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, she earned her Ph.D. in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.


Related Reports

Epilepsy - Special Topics - Epilepsy Special Topics New Treatments In Epilepsy US

More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to

View Details

Epilepsy | Disease Landscape and Forecast | G7 | 2020

Epilepsy, which afflicts approximately 4.7 million people in the major markets according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a...

View Details

Epilepsy - Access & Reimbursement - Detailed, Expanded Analysis (US)

Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and se...

View Details

Epilepsy - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US) Total

Epilepsy is a heterogeneous condition requiring individualized treatment—especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selectin...

View Details